We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

24 hedge funds and large institutions have $22M invested in Xilio Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

39.89% more ownership

Funds ownership: 5.41% → 45.3% (+40%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

13% less capital invested

Capital invested by funds: $25.4M → $22M (-$3.4M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

35% less funds holding

Funds holding: 37 → 24 (-13)

63% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 19

Holders
24
Holders Change
-13
Holders Change %
-35.14%
% of All Funds
0.3%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.02%
New
7
Increased
7
Reduced
8
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$1.13M
2
CP
Caligan Partners
New York
+$918K
3
SCM
Stonepine Capital Management
Oregon
+$452K
4
Renaissance Technologies
Renaissance Technologies
New York
+$204K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$112K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.56M
2
SC
Stempoint Capital
New York
-$1.3M
3
EAM
Empery Asset Management
New York
-$757K
4
GCM
Ghisallo Capital Management
Massachusetts
-$538K
5
Citadel Advisors
Citadel Advisors
Florida
-$279K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$5.58M +$1.13M +137,401 +26%
GS
2
Gilead Sciences
California
$5.47M – – –
FLSM
3
Frazier Life Sciences Management
California
$3.55M -$16 -2 -0%
SCM
4
Sio Capital Management
New York
$1.28M -$25 -3 -0%
VCM
5
Vanguard Capital Management
Pennsylvania
$1.04M +$1.01M +123,660 New
CP
6
Caligan Partners
New York
$943K +$918K +112,128 New
MC
7
Merck & Co
New Jersey
$891K -$8 -1 -0%
SCM
8
Stonepine Capital Management
Oregon
$540K +$452K +55,143 +611%
Morgan Stanley
9
Morgan Stanley
New York
$484K -$20.4K -2,496 -4%
Renaissance Technologies
10
Renaissance Technologies
New York
$417K +$204K +24,965 +101%
AIIC
11
AJU IB Investment Company
South Korea
$401K -$8 -1 -0%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$313K +$112K +13,699 +58%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$307K -$8 -1 -0%
VFT
14
Vanguard Fiduciary Trust
Pennsylvania
$239K +$233K +28,475 New
GCP
15
GSA Capital Partners
United Kingdom
$143K +$52.2K +6,377 +60%
VCIM
16
Velan Capital Investment Management
Georgia
$120K +$17.5K +2,142 +18%
GCM
17
Ghisallo Capital Management
Massachusetts
$116K -$538K -65,716 -83%
State Street
18
State Street
Massachusetts
$112K -$25 -3 -0%
Carson Wealth (CWM LLC)
19
Carson Wealth (CWM LLC)
Nebraska
$35.4K +$34.4K +4,206 New
UBS Group
20
UBS Group
Switzerland
$34K +$32.9K +4,023 +26,820%
JP Morgan Chase
21
JP Morgan Chase
New York
$1.98K +$1.97K +240 New
VGA
22
Vanguard Global Advisers
Pennsylvania
$1.77K +$1.72K +210 New
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$1K +$745 +91 New
KFI
24
Key Financial Inc
Pennsylvania
$496 – – –
Point72 Asset Management
25
Point72 Asset Management
Connecticut
– -$2.56M -285,714 Closed
1
2

XLO Hedge Fund Activity: Q1 2026 in Review

24 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2026, worth a combined $22M — down 13% from $25.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of XLO and 7 opened new positions — a net loss of 12 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $1.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.56M sold.

  • 24 institutional investors held Xilio Therapeutics (XLO) as of Q1 2026, down from 37 in Q4 2025.
  • Funds reported $22M of Xilio Therapeutics stock for Q1 2026, down 13% quarter-over-quarter.
  • 7 funds opened new Xilio Therapeutics positions in Q1 2026 and 19 closed out, a net change of -12 holders.
  • The largest Xilio Therapeutics buyer in Q1 2026 was Bain Capital Life Sciences Investors, an estimated $1.13M added.
  • The largest Xilio Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $2.56M sold.

Based on aggregated 13F filings for Q1 2026.